Compare Global X CleanTech (CTEC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X CleanTech vs Zoetis Inc — how do they compare? Global X CleanTech trades at $60.14, while Zoetis Inc trades at $73.61 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Global X CleanTech pays none, and Global X CleanTech is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| CTEC | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $156.76 |
52-Week Low | $41.08 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTEC trades at $60.14, up 3.68% today, with a bullish technical signal from moving averages but bearish oscillators. Key resistance is at $60, with support at $58. The company has announced a dividend of $0.07 per share payable in July 2026. Financial ratios such as P/E and P/S are not available in the provided data.
The outlook is mixed; technical strength suggests potential near-term gains, but overbought RSI signals caution. The dividend announcement may attract income investors. Risks include reliance on technical momentum without clear fundamental data and market volatility. Investors need updated financials for a complete assessment.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X CleanTech
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
